Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment with its lead drug candidate ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). In a recent interview on the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed outlined the company's strategy and the promising preclinical data supporting ONC010's development.
Mohamed emphasized two key selectivity mechanisms that distinguish ONC010 from conventional therapies. First, the drug employs synthetic lethality, designed to preferentially kill cancer cells that have lost PTEN or SHP-1, while sparing healthy cells. Second, nanoparticle delivery aims to concentrate the drug within tumor tissue, further enhancing its therapeutic index. These mechanisms are intended to maximize efficacy while minimizing systemic toxicity, a common challenge in oncology.
Preclinical research conducted at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor exhibited single-agent antitumor activity, was well-tolerated at tested doses, and prolonged survival relative to controls. These findings provide a strong rationale for advancing ONC010 into human trials, which the company is planning as part of its first-in-human clinical program.
"The preclinical results are encouraging, and we believe ONC010 could offer a new treatment option for patients with cancers that have limited responses to existing therapies," Mohamed said during the podcast. He also noted that the exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP positions Onco-Innovations as a leader in this emerging area of DNA damage response.
The importance of this announcement lies in its potential to address unmet needs in oncology. By targeting PNKP, a novel clinical target, Onco-Innovations is exploring a differentiated mechanism that could complement or overcome resistance to other treatments. The dual selectivity approach may reduce side effects and improve patient outcomes, particularly for those with PTEN or SHP-1 deficiencies, which are common in various cancers.
For investors and industry observers, the progress of ONC010 signals a critical step in translating preclinical promise into clinical reality. The company's focus on a first-in-human program underscores its commitment to bringing innovative therapies to market. As the oncology landscape evolves, approaches like PNKP inhibition could become integral to precision medicine.
To view the full press release, visit https://ibn.fm/XgpMR. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. For more information about BioMedWire, visit https://www.BioMedWire.com.
